Disease · EFO_0003913

angina pectoris

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. angina pectoris. Diseases, record EFO_0003913. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003913

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: angina pectoris; Open Targets
Open Targets ID: EFO_0003913; Open Targets
Other names: Angor Pectoris, Stenocardia, Stenocardias, angina, stable angina; Open Targets
MeSH: D000787; MeSH
MeSH: D060050; MeSH
NCI Thesaurus: C66914; NCI Thesaurus
Highest stage of its drugs: Approval, for 35 of its 107 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs107

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RANOLAZINE	CHEMBL1404	Small molecule	Approval	DailyMed and EMA Human Drugs	19	13	13	Drugs and targets
IVABRADINE	CHEMBL471737	Small molecule	Approval	EMA Human Drugs and TTD	11	4	4	Drugs and targets
NITROGLYCERIN	CHEMBL730	Small molecule	Approval	DailyMed and TTD	56	3	3	Drugs and targets
NICORANDIL	CHEMBL284906	Small molecule	Approval	TTD	4	3	3	Drugs and targets
ATORVASTATIN CALCIUM	CHEMBL393220	Small molecule	Approval	DailyMed and PMDA	67	1	1	Drugs and targets
ATENOLOL	CHEMBL24	Small molecule	Approval	DailyMed	48	1	1	Drugs and targets
METOPROLOL SUCCINATE	CHEMBL2356097	Small molecule	Approval	DailyMed	7	1	1	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	6	1	1	Drugs and targets
DILTIAZEM HYDROCHLORIDE	CHEMBL1697	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
TRIMETAZIDINE	CHEMBL203266	Small molecule	Approval	TTD	2	1	1	Drugs and targets

1 to 10 of 107

See all 107 drugs

Targets115

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor beta	10	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	9	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	9	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	9	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	9	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/779	Drugs and targets
ADRB2	Adrenergic receptor beta	5	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	4	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	4	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	4	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2983	Drugs and targets
P2RY12	P2Y purinoceptor 12	4	Purinergic receptor P2Y12 antagonist	Approval	https://conductscience.org/library/genes/64805	Drugs and targets

1 to 10 of 115

See all 115 targets

Trials53

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00644332	An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)	Phase 4	172	2012-07-02	Chronic Angina	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT01342029	Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia	Not applicable	142	2017-12-12	Microvascular Coronary Dysfunction (MCD)	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT00682565	PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina	Phase 2	94	2010-02-25	Heart Failure, Myocardial Ischemia, Angina Pectoris	OMECAMTIV MECARBIL	Its record names the disease	ClinicalTrials.gov
NCT02575833	Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)	Phase 2	89	2018-07-05	Stable Angina	ERENUMAB	Its record names the disease	ClinicalTrials.gov
NCT01294709	A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)	Phase 1	64	2014-09-10	Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor	TELCAGEPANT	Its record names the disease	ClinicalTrials.gov
NCT01948310	Effects of Ranolazine and Exercise on Daily Physical Activity Trial	Phase 4	38	2017-12-12	Chronic Stable Angina	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT02252406	Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome	Phase 4	33	2020-04-10	Stable Angina, Metabolic Syndrome	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT02147067	Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)	Phase 2	26	2019-05-21	Microvascular Angina	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT01435174	Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients	Phase 4	17	2014-06-25	End-stage Renal Disease, Cardiovascular Disease	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT03236311	A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI	Phase 2	10	2019-07-11	Microvascular Coronary Artery Disease	SAR-407899	Its record names the disease	ClinicalTrials.gov

1 to 10 of 53

See all 53 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ranolazine vs Placebo: deaths from any cause	14 of 142	11 of 142	284	NCT01342029	Trial comparisons
Ranolazine vs Placebo: serious adverse events	6 of 142	1 of 142	284	NCT01342029	Trial comparisons
Erenumab 140 mg vs Placebo: deaths from any cause	0 of 44	0 of 44	88	NCT02575833	Trial comparisons
Erenumab 140 mg vs Placebo: serious adverse events	0 of 44	1 of 44	88	NCT02575833	Trial comparisons
Ranolazine Plus Exercise vs Placebo Plus Exercise: deaths from any cause	0 of 18	0 of 19	37	NCT01948310	Trial comparisons
Ranolazine Plus Exercise vs Placebo Plus Exercise: serious adverse events	0 of 18	0 of 19	37	NCT01948310	Trial comparisons
Ranolazine Treated vs Placebo: deaths from any cause	0 of 16	0 of 17	33	NCT02252406	Trial comparisons
Ranolazine Treated vs Placebo: serious adverse events	0 of 16	0 of 17	33	NCT02252406	Trial comparisons
Ranolazine vs Placebo: deaths from any cause	0 of 11	0 of 11	22	NCT02147067	Trial comparisons
Ranolazine vs Placebo: serious adverse events	0 of 11	0 of 11	22	NCT02147067	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22278333	RESULT	1	PubMed
19136486	RESULT	1	PubMed
16875985	RESULT	1	PubMed
37889203	DERIVED	1	PubMed
35466050	DERIVED	1	PubMed
33840228	DERIVED	1	PubMed
33272036	DERIVED	1	PubMed
31829173	DERIVED	1	PubMed
30909832	DERIVED	1	PubMed
30293664	DERIVED	1	PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003913

GET https://conductscience.org/api/diseases/v1/EFO_0003913/drugs?page=2

API reference For AI assistants